Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Behavioral health constitutes a crucial yet frequently neglected component of overall wellness. The impact of mental and substance use disorders affects an astonishing 970 million individuals globally, contributing to an economic burden exceeding US $1 trillion each year. In spite of this escalating crisis, advancements in treatment and understanding have not kept pace with other medical fields. Alarmingly, less than half of those suffering from major depression, which is the most prevalent mental health disorder, achieve remission with existing therapies. Increased awareness has sparked a greater demand for services in a system that remains ill-equipped to address the extensive complexities of this need. There exists a significant evidence gap that hinders progress in research and innovation, largely due to the inherent challenges within behavioral health, such as intricate disease causes, a shortage of measurable biomarkers, and fragmented institutional approaches. Even after many years of dedicated research, we remain largely in the dark about how to effectively treat most behavioral health conditions, indicating a critical need for renewed focus and resources in this field. Ultimately, bridging this gap is essential for improving the lives of millions affected by these disorders.
Description
By leveraging visual analytics through TIBCO Spotfire®, PerkinElmer Signals Translational offers a comprehensive suite of tools designed to harmonize, manage, search, aggregate, and analyze extensive datasets consistently for translational research, all while ensuring scalability. This platform, driven by TIBCO Spotfire®, supports precision medicine initiatives by providing an unparalleled solution for biomarker discovery and patient stratification. The Linear Mixed Effect App (LME) within Signals Translational empowers researchers to evaluate the influence of various factors on specific phenotypes, allowing for adjustments related to random variables during analysis. Furthermore, it enables the identification of genes significantly affecting cancer stage progression, irrespective of patient origins. Notably, the LME models excel at addressing issues such as missing values and outliers, making them a robust choice for discovering potential biomarkers. Consequently, the integration of these advanced analytics tools enhances the efficacy of translational research in identifying key biomarkers that can lead to more personalized treatment approaches.
API Access
Has API
No
API Access
Has API
No
Integrations
Signals Research Suite
No
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
No
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
Yes
Mac
Yes
Linux
No
Chromebook
No
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
Yes
In Person
No
Types of Training
Training Docs
Yes
Webinars
Yes
Live Training (Online)
Yes
In Person
No
Vendor Details
Company Name
Holmusk
Founded
2015
Country
Singapore
Website
www.neuroblu.ai/
Vendor Details
Company Name
PerkinElmer
Founded
1937
Country
United States
Website
perkinelmerinformatics.com/products/clinical-translational/signals-translational/